The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.

Content from this campaign

Health & Healthcare

Novel Novartis Compound Shows Potential as Effective Therapy for Treating Drug Resistant Malaria
Today Novartis published proof of concept study results in the New England Journal of Medicine showing that its new antimalarial compound, KAF156, demonstrated activity against both vivax and falciparum malaria, including artemisinin-resistant parasites.

Health & Healthcare

At a Juncture in Malaria Eradication
We are at a juncture in malaria eradication. If we can sustain the extraordinary efforts of the past 15 years and continue to invest much needed resources, we stand a chance of reaching a malaria-free world within our generation. The upcoming fifth Replenishment Conference of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Canada represents an important milestone in the fight against malaria and also gives us a fantastic opportunity to take stock of successes and focus on the work ahead.

Events, Media & Communications

Malaria Experts and African Leaders Challenged to Maintain the Momentum and Win the Race for Malaria Elimination
Novartis convenes the 15th Annual National Malaria Control Program (NMCP) Best Practice Sharing Workshop today in Dakar, Senegal. Over the next two days, leading malaria experts and African leaders will discuss how to take on the challenge to win the race for malaria elimination.

Health & Healthcare

Preparing to Stop Drug-Resistant Malaria
No child should ever die from a mosquito bite. Yet, today, in an era of extraordinary medical advancement, a child dies of mosquito-borne malaria every two minutes. Last year, this agonizing blood disease caused by the malaria parasite claimed nearly half a million lives—most of them children.

Still, there’s unprecedented cause for optimism. After 15 years of coordinated efforts to fight malaria, we’re seeing progress: Malaria deaths have declined 60 percent since 2000, meaning more than six million lives have been saved. During that same period, an analysis by the Roll Back Malaria initiative shows that 57 countries have reduced malaria cases by 75 percent or more.

Health & Healthcare

Novartis Expands Partnership with Medicines for Malaria Venture to Develop Next-Generation Antimalarial Treatment
Novartis announced today that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV).

Health & Healthcare

More than 750 Million Anti Malaria Treatments for Adults and Children Provided Without Profit
Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes. Since 2001, working with a range of organizations, the Novartis Malaria Initiative – one of the pharmaceutical industry’s largest access-to-medicine programs – has provided more than 750 million treatments for adults and children, without profit, to more than 60 countries, contributing to a dramatic reduction of malaria deaths in Africa.

Health & Healthcare

Eradicating Malaria Through Innovation: Where Next After 2015?
To mark the inception of the "European Year of Development" earlier this year, and explore a renewed global health agenda for malaria post-2015, Novartis organized a debate in the European Parliament on eradicating malaria through innovation. Other speakers included representatives from the European Parliament, the European Commission, the Kenya Medical Research Institute and Medicines for Malaria Venture.

Health & Healthcare

About the Novartis Malaria Initiative
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...